Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Completed

Conditions studied: Renal Cell Carcinoma

In brief

This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy

Key facts

Study ID

NCT04883827

Run by

Vanderbilt-Ingram Cancer Center

People needed

180

Starts

2021-01-06

Expected to finish

2023-12-01

Last updated by the study team

2024-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Renal Cell Carcinoma with clear cell component
• Stage IV
• Receiving IO-containing regimen
• Measurable disease per RECIST 1.1

You may not qualify if…

• Active cancer (exclusion criteria only for healthy patient cohort)

Where it is running

• Tennessee Valley Health Care System — Nashville, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.